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ABSTRACT
Introduction Consensus on the best treatment
regimens for patients with isoniazid-resistant TB is
limited; global treatment guidelines differ. We undertook
a systematic review and meta-analysis using
mixed-treatment comparisons methodology to provide an
up-to-date summary of randomised controlled trials
(RCTs) and relative regimen efﬁcacy.
Methods Ovid MEDLINE, the Web of Science and
EMBASE were mined using search terms for TB, drug
therapy and RCTs. Extracted data were inputted into
ﬁxed-effects and random-effects models. ORs for all
possible network comparisons and hierarchical rankings
for different regimens were obtained.
Results 12 604 records were retrieved and 118
remained postextraction, representing 59 studies—27
standalone and 32 with multiple papers. In comparison
to a baseline category that included the WHO-
recommended regimen for countries with high levels of
isoniazid resistance (rifampicin-containing regimens using
fewer than three effective drugs at 4 months, in which
rifampicin was protected by another effective drug at
6 months, and rifampicin was taken for 6 months),
extending the duration of rifampicin and increasing the
number of effective drugs at 4 months lowered the odds
of unfavourable outcomes (treatment failure or the lack
of microbiological cure; relapse post-treatment; death
due to TB) in a ﬁxed-effects model (OR 0.31 (95%
credible interval 0.12–0.81)). In a random-effects model
all estimates crossed the null.
Conclusions Our systematic review and network meta-
analysis highlight a regimen category that may be more
efﬁcacious than the WHO population level
recommendation, and identify knowledge gaps where
data are sparse.
Systematic review registration number
PROSPERO CRD42014015025.
INTRODUCTION
In 2014, 3.3% of new patients with TB globally
and 20% of those previously treated had
multidrug-resistant (MDR) TB, that is, resistance to
both of the ﬁrst-line drugs isoniazid (INH) and
rifampicin (RIF).1 Outside of Eastern Europe
13.9% of incident disease was estimated to be INH-
resistant 1994–2009, but 44.9% within Eastern
Europe.2 The loss of INH, a drug with a relatively
low risk of adverse events (AEs) and potent early
bactericidal activity, would compromise the
treatment of active TB.2 On an individual level,
patients with INH-monoresistant disease are at a
theoretically greater risk of developing MDR than
those with drug-sensitive TB due to the requirement
for only a single additional resistance mutation,
with the associated risk of a need for more expen-
sive, toxic and lengthy treatment regimens.3 At a
population level, inadequate treatment of monore-
sistant disease leading to an increased prevalence of
MDR could be highly detrimental for TB control
programmes.
In countries with ‘high’ levels of INH resistance
in new patients with TB, the WHO has recom-
mended a 2 month intensive phase of INH, RIF,
pyrazinamide (PZA) and ethambutol (EMB) fol-
lowed by a 4 month continuation phase of INH,
RIF and EMB in patients without INH susceptibility
testing or where results are not available before the
continuation phase.3 If detailed individual-level drug
susceptibility results are accessible more comprehen-
sive recommendations are made, for example, 6–9
months of RIF, PZA and EMB (plus or minus a
ﬂuoroquinolone) for INH-monoresistant or INH
and streptomycin (STM)-resistant disease.4 The
American Thoracic Society (ATS) recommends that
Key messages
What is the key question?
▸ What regimen is the most efﬁcacious for
treating patients with isoniazid-resistant TB?
What is the bottom line?
▸ In comparison to a baseline category that
included the WHO’s recommended regimen for
countries with high levels of isoniazid
resistance, this systematic review and
meta-analysis identiﬁed that extending the
duration of rifampicin and increasing the
number of effective drugs present at 4 months
increases efﬁcacy.
Why read on?
▸ Treatment guidelines for isoniazid-resistant TB
are diverse and lack consensus, despite the
burden of such resistance globally; our
systematic review summarises the evidence
behind recommending different regimens.
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INH-resistant TB is treated with a 6 month regimen of RIF, PZA
and EMB (plus a ﬂuoroquinolone for extensive disease).5 The
National Institute for Health and Care Excellence (NICE), UK,
recommends a 9 month regimen (10 months where disease is
extensive) of 2 months of RIF, PZA and EMB then 7 months of
RIF and EMB.6 All three bodies recognise the need for further
research in this area.
Conventional meta-analyses only allow direct comparisons
between regimens contrasted within speciﬁc studies and are highly
limited in the inferences they can make about relative efﬁcacy.
Previous reviews of INH-resistant TB treatment have been
restricted by the methodology available.7–9 By comparison,
Bayesian hierarchical models use a network approach that gener-
ates indirect comparisons of regimens for incorporation into infer-
ences of relative efﬁcacy.10 11 We undertook a systematic review
and meta-analysis using this approach to provide a vital updated
evidence summary of randomised controlled trials (RCTs) of the
treatment of non-MDR INH-resistant TB (referred to throughout
as ‘INH resistant’),6 and to assess relative regimen efﬁcacy at
preventing negative outcomes (treatment failure or the lack of
microbiological cure; relapse post-treatment; death due to TB).
METHODS
Data sources and searches
Ovid MEDLINE, the Web of Science and EMBASE were mined
using search terms for TB, drug therapy and RCTs (see online
supplementary ﬁle 1). Reference lists of included papers and
review articles were also searched. This review was registered
with PROSPERO-CRD42014015025.
Study selection
Inclusion criteria:
▸ RCTs indexed by the 21st of January 2015 of antimicrobial
regimens for TB disease
▸ RCT used culture to conﬁrm disease and drug sensitivity
tested
▸ Treatment outcomes and/or relapses post-treatment extract-
able either speciﬁcally for patients with INH-resistant strains
or for the entire study population if ≥85% of that popula-
tion had INH-resistant disease
▸ All INH resistance proﬁles retained, provided strains not
MDR
▸ No language restrictions
Exclusion criteria:
▸ Trials in animals
▸ Trials that were not RCTs comparing at least two antimicro-
bial regimens
HRS screened all (and H-AH 10%) of the retrieved records
from the de-duplicated titles to full texts. H-AH also independ-
ently undertook the ﬁnal stage of full text screening of all arti-
cles identiﬁed as potentially being includable by HRS. Where
consensus was not achieved a third reviewer (IA) was available
to resolve discrepancies.
Data extraction and quality assessment
Two reviewers (HRS and H-AH) independently extracted publi-
cations into a standardised predesigned spreadsheet (see online
supplementary ﬁle 2). Discrepancies were resolved by discussion
and study authors contacted if necessary. Publications not
written in a language ﬂuently spoken by HRS or H-AH were
extracted by an additional reviewer.
HRS and H-AH independently assessed study quality using
the Cochrane Collaboration’s tool for evaluating bias (see online
supplementary ﬁle 2).12 A sensitivity analysis excluding studies
deemed at high risk of bias across all domains was planned.
Data synthesis
Treatment regimens were categorised via a decision tree that
reﬂected the roles of particular drugs, the importance of RIF
and treatment duration (ﬁgure 1 and table 1). The protection of
RIF by another effective drug (ED) was assessed at 6 months to
reﬂect the usual treatment length for drug-sensitive cases. In the
absence of a consistent deﬁnable intensive phase across regimens
we chose to assess the number of EDs at 4 months, double the
usual intensive phase length in drug-sensitive treatment regi-
mens. If regimens were shorter than 6 months the drugs at the
end were considered for the question ‘was RIF protected by
another drug at six months?’
A composite negative outcome of (1) death due to TB, (2)
treatment failure (a lack of clinical improvement necessitating a
Figure 1 Treatment regimen
categorisation. Regimen categorisation
ﬂow chart for main analysis. Second
question includes RIF in the
calculation. Bolded text after ﬁnal
question indicates regimen category
(table 1) present in main network
(ﬁgure 3B). *Levamisole and diphenyl
thiourea compound SU 1906 not
counted as effective protection. INH,
isoniazid; RIF, rifampicin.
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regimen change) or no microbiological cure and (3) relapse
post-treatment was generated. Cures and relapses were prefer-
ably deﬁned by culture conversion. AEs were extracted (see
online supplementary ﬁle 2), but not reported consistently
enough to be included.
Statistical analysis
Direct evidence was initially analysed using a standard pairwise
meta-analysis in Stata V.13.1 using metan (see online supplemen-
tary ﬁle 3).13 Similar to that mentioned earlier,14 a mixed-
treatment comparisons (MTC) approach was then used, which
extends standard meta-analysis to multiple treatments. Brieﬂy,
ﬁxed-effects and random-effects models as described by Dias
et al15 were ﬁtted within a Bayesian framework, producing
point estimates, 95% credible intervals (CrI) and treatment
rankings (see online supplementary ﬁle 3, which also documents
our approach to assess network inconsistency and publication
bias).
RESULTS
Post-deduplication 12 604 records were retrieved (see online
supplementary ﬁle 4). A 98% consensus was achieved during
double screening. After full text extraction (see online supple-
mentary ﬁle 5) 118 were included, representing 59 studies—27
standalone and 32 with multiple papers.16–74 In the latter
instance baseline data were usually taken from the earliest publi-
cation and relapses from the latest.
Forty-three studies provided data on patients with TB
with non-MDR INH-monoresistant strains,17–19 21–36 38–42
44–48 50–52 56 57 60–62 64 66 68 71 73 74 36 on patients with TB
with INH-resistant and STM-resistant strains16 19–25 27–38 40
42–45 47 49 51–53 59 60 62 63 65 66 and eight on more complex
non-MDR resistance patterns (see online supplementary
ﬁle 6).26 54 55 58 67 69 70 72 One study contained INH and
p-aminosalicylic acid-resistant patients that were not extracted as
one treatment arm was composed solely of these two drugs.64
In ﬁve studies the results extracted were not for pure
INH-resistant populations, but the proportion resistant to INH
was above our threshold of 85% and not substantially different
by arm.43 50 69 72 74
Forty-ﬁve studies were not solely focused on patients with
drug-resistant TB.17–26 28–42 44 45 47 51–54 56–64 66 67 71 73 One
had speciﬁc inclusion criteria for extrapulmonary (abdominal)
disease.17 No studies were conducted solely in children;
one looked speciﬁcally at HIV-positive individuals.58 One did
not randomise at the individual level.51 Ten contained more
than 100 analysable patients with INH-resistant
disease16 18 20 27 43 46 47 49 69 70 and 29 over
50.16 18 20 27 29 30 35 36 38 40 42–49 51 55 57 60 65 66 68–72 Two
reported data before patients had completed the full length of
assigned treatment; we recorded regimen length appropri-
ately.60 71 Twenty-two did not assess relapse post-
treatment.17 21 37 42 46 47 49 50 53–55 59 60 63–65 67 68 70 71 73 74
Follow-up time after the end of treatment ranged from
3 months to 7.5 years. The majority of studies reporting relapses
deﬁned them on the basis of culture status (usually two or more
positive cultures in a 3-month period).
Quality
Across four of the six quality domains (randomisation, alloca-
tion concealment, blinding of participants and personnel, blind-
ing of outcome assessment) many of RCTs did not record
sufﬁcient information to assess the risk of bias (see online sup-
plementary ﬁle 7). One study was considered at high risk due to
lacking allocation concealment,27 ﬁve lacked blinding of partici-
pants and personnel (four of these did not blind outcome
assessment)17 19 57 58 69 and 40 had high levels of attrition
(linked to the length of follow-up).18 22–29 31 33 34 36–40
42–47 50 51 53 55–57 60–62 64 66–70 72 74 No studies were at high
risk of bias across all domains.
Treatment of patients with INH-resistant TB
Data were available for 11 of a potential 14 regimen categories
(ﬁgure 1 and table 1). Regimens were categorised as per table 1,
for example, RIF ED<3 Pr6 D>6m represents a RIF-containing
regimen using fewer than three ED at 4 months, where RIF was
protected by an ED at 6 months (Pr6), and the overall duration
(D) of RIF was greater than 6 months. Using data from any
INH resistance pattern, few pairwise inferences were available
of the relative efﬁcacy (ﬁgure 2). In two comparisons one
study showed outlying results.20 Considerable heterogeneity
was observed for one comparison, likely due to the same study,
otherwise ﬁxed effects were deemed appropriate.
Given such limitations we undertook a network meta-analysis.
Regimen category RIF ED<3 Pr6 D=6m, in which the
WHO-recommended regimen for countries with high levels of
INH resistance sits, was set as the network baseline (ﬁgure 3A);
12 studies were included in this category. Model ﬁtting pro-
ceeded as described in online supplementary ﬁle 8; one incon-
sistent study,20 identiﬁed as an outlier in the pairwise analysis,
was excluded (ﬁgure 3B). Results are presented from both
ﬁxed-effects and random-effects models (table 2 and ﬁgures 4
and 5). In the ﬁxed-effects model regimen category RIF ED≥3
Pr6 D>6m (present in two studies) was predicted to have a
lower likelihood of a negative outcome than category RIF
ED<3 Pr6 D=6m (OR 0.31 (95% CrI 0.12–0.81)); RIF ED<3
D>6m and RIF ED<3 D=6m also had low OR estimates, but
their CrIs crossed the null (0.17 (0.02–1.07) and 0.48 (0.20–
1.14), respectively) (table 2). In the random-effects model all
effect estimates crossed the null. Categories RIF ED<3 D>6m,
RIF ED<3 D=6m and RIF ED≥3 Pr6 D>6m ranked highest in
Table 1 Regimen category codes
RIF
containing?
# of
effective
drugs (ED)
up to 4m?
At 6m RIF
protected (Pr6)
by another
effective drug?
Overall
(RIF)
duration
(D) Code
No <3 N/A <6m ED<3 D<6m
No <3 N/A ≥6m ED<3 D≥6m
No ≥3 N/A ≥6m ED≥3 D≥6m
Yes <3 No <6m RIF ED<3 D<6m
Yes <3 No 6m RIF ED<3 D=6m
Yes <3 No >6m RIF ED<3 D>6m
Yes <3 Yes 6m RIF ED<3 Pr6
D=6m
Yes <3 Yes >6m RIF ED<3 Pr6
D>6m
Yes ≥3 No <6m RIF ED≥3 D<6m
Yes ≥3 Yes 6m RIF ED≥3 Pr6
D=6m
Yes ≥3 Yes >6m RIF ED≥3 Pr6
D>6m
Encoded regimen categories (figure 1) present in the main network.
4m, 4 months; 6m, 6 months; D</=/>6m, overall RIF duration or duration of the
entire regimen if RIF not present; N/A, not applicable; Pr6, protected at 6 months; RIF,
rifampicin.
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the ﬁxed-effects model, although with substantial uncertainty
for the former (ﬁgure 5A). This held true in the random-effects
model (ﬁgure 5B). Absolute differences in the proportion of
patients with a negative outcome (table 2) showed that in the
ﬁxed-effects model RIF ED≥3 Pr6 D>6m reduced the baseline
proportion of 0.19 by 0.12, that is, approximately seven
Figure 2 Pairwise direct effects
forest plots across all isoniazid
resistance proﬁles. Pairwise direct
effects forest plots for the four regimen
pairs where such comparisons were
possible. Regimen RIF ED<3 D<6m the
baseline for plots (A–C) and regimen
RIF ED<3 D=6m for plot (D). Regimen
(A) RIF ED<3 D=6m, (B) RIF ED<3 Pr6
D=6m, (C) RIF ED≥3 D<6m, (D) RIF
ED<3 Pr6 D=6m the comparator. In
analysis (D) study STS/BMRC had no
events in either arm. Vertical solid line
—null hypothesis. Vertical dotted line
summary estimate. AWG/BMRC,
Algerian Working Group/British
Medical Research Council Cooperative
Study; EABMRC, East African British
Medical Research Council Study; ECA/
BMRC, East and Central African/British
Medical Research Council; ED, effective
drugs; HKCS/BMRC, Hong Kong Chest
Service/British Medical Research
Council; RIF, rifampicin; STS/BMRC,
Singapore TB Service/British Medical
Research Council.
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remaining negative outcomes per 100 (equivalent change in
random-effects model 16 patients to 8).
Sensitivity analyses were undertaken to examine the impact of
changing the regimen categorisation of a single arm of one
study where grouping was uncertain as reported outcomes were
not fully separated by PZA usage (see online supplementary
ﬁle 10).66 Relatively little impact on the effect estimates was
observed.
In a network adjusted for the dose of RIF, RIF ED≥3 Pr6
D>6m remained the only category in the ﬁxed-effects model
where the odds of a negative outcome were lower than that of
the baseline and did not cross the null (0.22 (0.06 to 0.75)) (see
online supplementary ﬁle 11). The impact of taking a lower
dose of RIF was not consistent, with a high degree of
uncertainty.
The relative efﬁcacy of different regimens may change if there
is additional drug resistance present. Restricting our analysis to
patients with INH-monoresistant strains left 43 studies, of
which 23 tested the same regimen group in all arms and a
further three had no events (see online supplementary ﬁle 12).
Of the remaining 17 studies 11 had arms condensed together.
In both models uncertainty was very great due to data sparsity
(eg, one study examined RIF ED≥3 Pr6 D>6m), preventing
ﬁrm conclusions.
Inconsistency
Effect estimates from both ﬁxed-effects and random-effects pair-
wise meta-analyses without the inconsistent study were com-
pared with those from the random-effects MTC to evaluate if
evidence was systematically inconsistent or simply randomly
variable. Only two pairwise comparisons were made by more
than two studies. Estimates from both were highly similar to
those from the random-effects network meta-analysis, suggest-
ing limited detectable inconsistency: RIF ED<3 D<6m versus
RIF ED<3 D=6m—ﬁxed pairwise 0.36 (95% CI 0.17 to 0.77),
random pairwise 0.41 (95% CI 0.16 to 1.05), random network
0.41 (95% CrI 0.11–1.10); RIF ED<3 D<6m versus RIF
ED<3 Pr6 D=6m—ﬁxed pairwise 0.85 (95% CI 0.37 to 1.95),
random pairwise 0.87 (95% CI 0.38 to 2.01), random network
0.76 (95% CrI 0.18–2.28).
Publication bias
Little evidence was seen of small-study effects for the four pos-
sible pairwise comparisons with the inconsistent study included
(see online supplementary ﬁle 13). The Harbord test was under-
taken where a comparison was made by more than two studies:
p value 0.07 for RIF ED<3 D<6m versus RIF ED<3 D=6m,
0.38 for RIF ED<3 D<6m versus RIF ED<3 Pr6 D=6m.
DISCUSSION
This is the ﬁrst systematic review for non-MDR INH-resistant
TB to use a MTC methodology to infer the relative efﬁcacy of
different treatment regimens. When studies of patients with
strains of any non-MDR INH resistance proﬁle were included in
our network, regimen category RIF ED≥3 Pr6 D>6m (a
RIF-containing regimen using three or more ED at 4 months, in
which RIF is protected at 6 months, and RIF was taken for
more than 6 months) appeared better than RIF ED<3 Pr6
D=6m (a RIF-containing regimen using fewer than three ED at
4 months, in which RIF was protected at 6 months, and RIF
was taken for 6 months; category includes WHO-recommended
regimen for countries with a high burden of INH resistance). In
a network restricted to patients with INH-monoresistant disease
data sparsity made conclusions difﬁcult to draw.
Figure 3 Data network. Data networks (A) for the main analysis containing all isoniazid resistance patterns, (B) for the main analysis excluding
the inconsistent study. Thickness of lines and numbers indicate the number of studies making this comparison. *One study arm classiﬁable as RIF
ED≥3 Pr6 D=6m, RIF ED<3 Pr6 D=6m or RIF ED<3 D=6m compared with RIF ED<3 D=6m; here listed as RIF ED≥3 Pr6 D=6m as per main
analysis. ED, effective drugs; RIF, rifampicin.
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Our network meta-analysis was constrained by the number of
RCTs documenting outcomes for patients with INH-resistant
disease and the number of individuals within these RCTs.
Additionally, Bayesian methodologies have their own limitations
when using sparse data. Indeed, the regimen rankings and effect
estimates observed from our MTC are not fully consistent with
what could be predicted from our regimen categories; data
availability will play a major role here. Such a categorisation
process was necessary, however, to allow the MTC approach.
The uncertainty of our estimates is acknowledged, particularly
with the random-effects models. We could not adjust for cluster-
ing in the cluster randomised study due to the nature of the
data presented in that publication,51 although we expect the
impact of this to be relatively small. We did not speciﬁcally strat-
ify for the dose of particular drugs aside from RIF during our
analysis; however, dosing was generally consistent across
included RCTs.
The nature of the included studies introduced speciﬁc limita-
tions. When INH monoresistance was reported resistance
testing was not necessarily performed for other drugs. Relative
levels of INH resistance were only reported in one study.73 INH
resistance mutations were not reported, which was unfortunate
given observational reports associating, for example, katG315
with negative treatment outcomes.75 Extraction of
intention-to-treat data was not possible for all studies. Some
reported results speciﬁcally for unfavourable outcomes as
deﬁned, and in others this was calculated using data for favour-
able outcomes, which were not necessarily the opposite. Not all
studies reported all three of the negative outcomes assessed;
outcomes were not always culture conﬁrmed. Data on AEs were
minimal. We could not stratify by treatment adherence with the
data available. The absence of signiﬁcant numbers of studies in
HIV-positive patients, children and individuals with extrapul-
monary disease meant that restricted analysis examining these
particular patient populations were not possible; this could
introduce bias to the network if particular drug regimens were
only trialled in speciﬁc settings.
In 1986, Mitchison and Nunn9 undertook a review of 12 (11
published) British Medical Research Council RCTs, which had
tested different treatment regimens in patients with pulmonary
TB with initial drug resistance. In the absence of a formal
meta-analysis, they concluded that the sterilising ability of a
regimen was not substantially altered in individuals with initial
resistance to INH or STM. The number of drugs in the regimen
and duration of RIF were thought to be inﬂuential, for example
four to ﬁve drugs including (INH and) RIF in a 6 month
Table 2 ORs, relative ranks and absolute proportion difference from fixed-effects and random-effects network meta-analyses across all
isoniazid resistance profiles
OR (95% CrI) Rank (95% CrI) Proportion difference (95% CrI)
Treatment Fixed effects Random effects Fixed effects Random effects Fixed effects Random effects
ED<3 D<6m 3.47 (1.08–11.55) 4.38 (0.50–52.41) 11 (8–11) 11 (4–11) 0.26 (0.01–0.52) 0.29 (−0.09–0.74)
ED<3 D≥6m 2.54 (1.19–5.59) 2.50 (0.62–10.36) 10 (8–11) 10 (5–11) 0.18 (0.03–0.34) 0.16 (−0.07–0.43)
ED≥3 D≥6m 0.91 (0.35–2.30) 0.95 (0.15–6.21) 6 (3–9) 6 (2–10) −0.01 (−0.14–0.14) −0.01 (−0.20–0.31)
RIF ED<3 D<6m 1.00 (0.52–1.95) 1.32 (0.44–5.52) 6 (4–9) 7 (4–10) 0.00 (−0.11–0.10) 0.04 (−0.13–0.25)
RIF ED<3 D=6m 0.48 (0.20–1.14) 0.53 (0.13–2.20) 3 (2–6) 3 (1–7) −0.09 (−0.20–0.02) −0.07 (−0.23–0.09)
RIF ED<3 D>6m 0.17 (0.02–1.07) 0.19 (0.01–3.36) 1 (1–6) 1 (1–9) −0.15 (−0.26–0.01) −0.12 (−0.28–0.19)
RIF ED<3 Pr6 D=6m Baseline Baseline 6 (3–9) 6 (2–9) Baseline Baseline
RIF ED<3 Pr6 D>6m 1.01 (0.39–2.62) 0.85 (0.12–5.25) 6 (3–10) 5 (1–11) 0.00 (−0.13–0.17) −0.02 (−0.20–0.30)
RIF ED≥3 D<6m 1.60 (0.59–4.35) 1.89 (0.40–10.27) 9 (4–10) 9 (3–11) 0.08 (−0.08–0.28) 0.10 (−0.13–0.43)
RIF ED≥3 Pr6 D=6m 0.98 (0.24–4.57) 1.04 (0.13–9.25) 6 (2–11) 6 (1–11) 0.00 (−–0.16–0.31) 0.01 (−0.19–0.44)
RIF ED≥3 Pr6 D>6m 0.31 (0.12–0.81) 0.45 (0.07–4.32) 2 (1–4) 3 (1–9) −0.12 (−0.23–0.02) −0.08 (−0.24–0.23)
Main results from the network depicted in figure 3B. Baseline proportion with a negative outcome 0.19 (95% CrI 0.12–0.29) in the fixed-effects model and 0.16 (95% CrI 0.07–0.31) in
the random-effects model.
CrI, credible interval; ED, effective drugs; Pr6, protected at 6 months; RIF, rifampicin.
Figure 4 Forest plots from
ﬁxed-effects and random-effects
network meta-analyses across all
isoniazid resistance proﬁles. Forest
plots of treatment comparisons from
the network depicted in ﬁgure 3B. (A)
Fixed-effects and (B) random-effects
derived ORs on a log scale with 95%
credible interval. Vertical line—null
hypothesis. ED, effective drugs; RIF,
rifampicin.
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regimen was deemed beneﬁcial. Our review included all of these
published studies and our results were not dissimilar.
Of the two Menzies et al8 systematic reviews published in
2009 the ﬁrst, which sought to determine the effectiveness of
the WHO-recommended retreatment regimen at that time using
meta-regression, is more similar to our analysis. This study
found no RCTs of the retreatment regimen, but concluded that,
when considering the incidence rate of treatment failure or
relapse, a RIF duration of 2 months or less, having few drugs in
the intensive phase, and having therapy delivered twice weekly
throughout worsened both outcomes. In comparison, our sys-
tematic review encompassed a highly dissimilar set of publica-
tions (including new RCTs and an update) and our differing
analytical technique may have reduced the likelihood of bias
(see online supplementary ﬁle 14). Even so, our results were
similar in terms of the impact of RIF duration and the number
of drugs present early in a regimen.
As a baseline for our meta-analysis we chose the category that
contained the recommended WHO regimen for countries with
high levels of INH resistance in new patients with TB to ascer-
tain if there are more efﬁcacious regimens. Within this category
our review contained one study that evaluated this regimen
(although with slightly altered daily doses and in abdominal
TB), in which no INH-resistant patients had a negative
outcome.17 The NICE-recommended regimen would be
grouped as RIF ED<3 Pr6 D>6m within our groupings and the
ATS regimen as RIF ED≥3 Pr6 D=6m; these two categories
obtained middling ranks in our analysis, but we did not ﬁnd
includable studies speciﬁcally of either. We did not choose the
WHO-recommended regimen for INH-monoresistant or
INH-resistant and STM-resistant disease where individual-level
drug susceptibility patterns are known as our baseline due to
the lack of such testing in many countries. Although no studies
speciﬁcally tested this regimen it sits either in category RIF
ED≥3 Pr6 D=6m or RIF ED≥3 Pr6 D>6m, the latter of which
was the most efﬁcacious in our network. RIF ED≥3 Pr6 D>6m
contained two trialled regimens: (1) seven and a half months of
INH, STM, RIF and PZA administered daily for the ﬁrst month
and a half and then intermittently (apart from the INH) and (2)
12 months of EMB, morphazinamide (a drug closely related to
PZA with more unfavourable AE proﬁle)76 77 and RIF, adminis-
tered daily.
Ultimately, decisions as to the best regimen to use within a
particular country will also depend on drug availability, cost and
AEs. Category RIF ED≥3 Pr6 D>6m encompasses a variety of
regimens; those reported here contain relatively cheap drugs,
but also lengthy periods of components associated with a high
likelihood of AEs. Precise recommendations can thus not be
made without additional studies within this category. Regimens
that do not use any INH, for example those trialled in the
Figure 5 Histograms of relative ranks from ﬁxed-effects and random-effects network meta-analyses across all isoniazid resistance proﬁles. Relative
treatment ranks of treatment comparisons from the network depicted in ﬁgure 3B. (A) Fixed effects. (B) Random effects. ED, effective drugs; RIF,
rifampicin.
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recent Rifaquin study, could also be useful for effective
treatment.78
As Xpert MTB/RIF is rolled out globally many countries may
switch to only undertaking further drug sensitivity testing on
strains found to be genotypically RIF resistant. As such,
non-MDR INH resistance may be increasingly underdiagnosed,
and thus generally treated with the short-course regimen
2 months of INH EMB PZA RIF followed by 4 months of INH
RIF. In our network this regimen falls into the category RIF
ED<3 D=6m, for which the CrI in all models overlapped the
null.
In our systematic review and network meta-analysis, against a
baseline category of RIF-containing regimens with less than
three ED at 4 months, where RIF was protected at 6 months
and RIF was taken for 6 months, we demonstrate the efﬁca-
ciousness of extending the duration of RIF and increasing the
number of ED at 4 months, with a potential reduction in nega-
tive outcomes of ∼70%. By undertaking this work, we have
identiﬁed further efﬁcacious regimens for INH-resistant TB, a
target of future research listed by WHO in their treatment guid-
ance.3 Although more evidence was found for efﬁcacious regi-
mens than during our companion systematic review of
treatment regimens for RIF-monoresistant disease,79 we clearly
demonstrate the need for further studies of non-MDR
INH-resistant TB speciﬁcally in HIV-positive individuals and
children, as well as the efﬁcacy of EMB in such regimens.3
Indeed, we agree with NICE that ‘[r]andomised controlled trials
are needed to compare different anti-TB regimens for
isoniazid-resistant TB, assessing mortality, treatment success or
treatment failure, rates of relapse and adverse events’,6 and the
ATS that ‘[d]eﬁnitive randomized or controlled studies have not
been performed among patients with… various patterns of drug
resistance’.5
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